Literature DB >> 7775421

Expression of the leukocyte-associated sialoglycoprotein CD43 by a colon carcinoma cell line.

D Baeckström1, K Zhang, N Asker, U Rüetschi, M Ek, G C Hansson.   

Abstract

The colon adenocarcinoma cell line COLO 205 secretes L-CanAg, a mucin-like glycoprotein carrying the carcinoma-associated sialyl-Lewis a carbohydrate epitope. In an attempt to identify its apoprotein, an NH2-terminal peptide sequence was obtained from purified L-CanAg. In all interpretable positions, this sequence showed 100% identity to the NH2-terminal of human CD43 (leukosialin, sialophorin), a plasma membrane-bound sialoglycoprotein hitherto only identified in leukocytes and other hematopoietic cells. An antiserum against deglycosylated L-CanAg and an anti-CD43 antiserum both immunoprecipitated a 61-kDa band, interpreted as the CD43 precursor, from COLO 205 cells as well as from the known CD43-expressing cell line HL-60. Results from immunoprecipitations following pulse-chase experiments and tunicamycin treatments were in agreement with earlier studies on the CD43 precursor. RNA blot analysis confirmed the expression of CD43 by the COLO 205 cell line, whereas three other colon carcinoma cell lines were negative. The glycosylation-dependent monoclonal antibody Leu-22, which recognizes leukocyte CD43, failed to bind L-CanAg, probably due to its much more extensive glycosylation. We conclude that L-CanAg is the secreted extracellular domain of a novel glycoform of CD43 and that CD43, if expressed in other carcinoma cells, may have escaped notice in studies relying on glycosylation-dependent monoclonal antibodies against leukocyte CD43.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7775421     DOI: 10.1074/jbc.270.23.13688

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Novel adapter protein AP162 connects a sialyl-Le(x)-positive mucin with an apoptotic signal transduction pathway.

Authors:  S Hartel-Schenk; A Gratchev; M L Hanski; D Ogorek; G Trendelenburg; M Hummel; M Höpfner; H Scherübl; M Zeitz; C Hanski
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

2.  Tumor cell MUC1 and CD43 are glycosylated differently with sialyl-Lewis a and x epitopes and show variable interactions with E-selectin under physiological flow conditions.

Authors:  J Fernandez-Rodriguez; O Dwir; R Alon; G C Hansson
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

Review 3.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

Review 4.  Perspectives on the significance of altered glycosylation of glycoproteins in cancer.

Authors:  Y J Kim; A Varki
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

5.  5-Aza-2'-deoxycytidine increases sialyl Lewis X on MUC1 by stimulating β-galactoside:α2,3-sialyltransferase 6 gene.

Authors:  Vishwanath B Chachadi; Helen Cheng; David Klinkebiel; Judith K Christman; Pi-Wan Cheng
Journal:  Int J Biochem Cell Biol       Date:  2010-12-17       Impact factor: 5.085

6.  An antiserum raised against the recombinant cytoplasmic tail of the human CD43 glycoprotein identifies CD43 in many mammalian species.

Authors:  T Szlanka; G K Toth; I Ocsovszki; G Keresztes
Journal:  Immunology       Date:  1999-01       Impact factor: 7.397

7.  Shedding and gamma-secretase-mediated intramembrane proteolysis of the mucin-type molecule CD43.

Authors:  Christian X Andersson; Julia Fernandez-Rodriguez; Sirle Laos; Dan Baeckström; Christian Haass; Gunnar C Hansson
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

8.  High level expression of CD43 inhibits T cell receptor/CD3-mediated apoptosis.

Authors:  Y W He; M J Bevan
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

Review 9.  Aberrant glycosylation as biomarker for cancer: focus on CD43.

Authors:  Franca Maria Tuccillo; Annamaria de Laurentiis; Camillo Palmieri; Giuseppe Fiume; Patrizia Bonelli; Antonella Borrelli; Pierfrancesco Tassone; Iris Scala; Franco Maria Buonaguro; Ileana Quinto; Giuseppe Scala
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.